Enliven Therapeutics, Inc.

ELVN

Enliven Therapeutics, Inc.

ELVN

Insider Sentiment (TTM):

Last Purchase:-Last Sale:2026-06-22Shares Purchased (TTM):0Shares Sold (TTM):1,562,085

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:59,404,155Shares Outstanding:62,799,326Institutional Ownership Pct.:94.59%

Earnings Market Reaction:

Filing Date:2026-08-05Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	136	132	99	102	119	102	124	101	97	149	100	74
Marketable Securities Current	760	320	364	376	371	188	189	191	216	171	153	190
Restricted Cash Current	-	-	0	0	0	0	0	0	0	0	0	-
Prepaid Expense And Other Assets Current	12	11	12	5	5	5	5	5	6	7	3	5
Assets Current	907	463	475	483	496	294	318	297	318	337	266	269
Property Plant And Equipment Net	0	0	0	0	0	0	0	1	1	1	1	1
Operating Lease Right Of Use Asset	2	0	0	0	1	1	0	0	0	0	0	0
Other Assets Noncurrent	1	1	1	7	7	7	7	7	8	4	4	4
Assets	910	465	476	491	504	303	326	305	327	343	272	274
Liabilities And Stockhold…
Restricted Cash Noncurrent	-	-	-	-	-	-	-	-	-	-	0	0
Liabilities Current
Accounts Payable Current	0	2	2	1	2	2	1	1	1	3	1	1
Liabilities Current	14	11	17	15	15	14	16	17	22	25	26	12
Other Liabilities Noncurrent	-	-	-	0	0	0	0	0	0	0	0	0
Liabilities	15	11	17	15	15	14	16	17	22	25	26	12
Stockholders Equity
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	-
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	1,300	824	806	793	786	560	553	508	502	495	400	397
Accumulated Other Comprehensive Income Loss Net Of…	-2	-0	0	0	-0	-0	0	0	-0	-0	0	-0
Retained Earnings Accumulated Deficit	-403	-371	-347	-317	-297	-272	-243	-220	-197	-177	-154	-135
Stockholders Equity	895	453	460	476	488	288	310	288	305	318	246	262
Liabilities And Stockholders Equity	910	465	476	491	504	303	326	305	327	343	272	274
Preferred Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	10	10
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Convertible Preferred Stock	-	-	-	-	-	-	-	-	-	-	0	0
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	200	100	100	100	100	100	100	100	100	100	100	100
Common Stock Shares Issued	73	61	59	59	59	49	49	47	47	47	41	41
Shares Outstanding	73	61	59	59	59	49	49	47	47	47	41	41

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-1.79%	24.30%	31.42%	-	-	-	-	-	-	-	-	-
2025	4.27%	4.22%	-5.83%	0.83%	-1.88%	17.19%	7.44%	-23.45%	30.30%	35.06%	53.91%	44.49%
2024	-12.27%	-6.07%	-2.72%	-0.37%	27.93%	28.39%	-1.47%	-5.33%	-15.27%	-7.89%	1.08%	-12.42%
2023	-	-	-	-6.45%	-22.03%	-37.27%	0.35%	19.83%	38.35%	68.11%	96.27%	95.58%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	64.07	40.32	28.66	32.95	32.58	21.06	19.99	17.44	14.39	13.47	10.28	22.24
Quick Ratio	63.21	39.38	27.92	32.60	32.25	20.72	19.70	17.14	14.13	13.21	10.16	21.81
Working Capital	893.18M	451.65M	458.31M	468.03M	480.41M	280.35M	302.21M	279.97M	296.02M	312.17M	240.26M	256.53M
Leverage & Debt
Debt to Equity	0.02	0.03	0.04	0.03	0.03	0.05	0.05	0.06	0.07	0.08	0.11	0.05
Interest Coverage TTM	-6.73	-6.81	-7.47	-7.43	-8.16	-7.43	-7.02	-6.90	-6.87	-6.88	-6.98	-7.70
Debt Ratio	0.02	0.02	0.03	0.03	0.03	0.05	0.05	0.06	0.07	0.07	0.10	0.04
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Per Share Metrics
Diluted EPS TTM	-1.60	-1.57	-1.83	-1.57	-1.92	-1.89	-1.89	-1.77	-1.72	-1.89	-2.01	-1.51
Free Cash Flow Per Share TTM	-1.09	-1.04	-1.24	-0.77	-0.89	-1.48	-1.56	-1.42	-1.50	-1.52	-1.73	-1.39
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Growth Metrics
Net Income Growth (1Y)	5.70%	4.16%	16.48%	14.07%	20.99%	19.14%	24.36%	37.97%	60.68%	82.08%	90.07%	45.56%
EPS Growth (1Y)	-16.77%	-16.98%	-3.24%	-11.33%	11.64%	0.08%	-6.09%	17.28%	36.90%	-19.82%	-83.29%	-88.55%
Valuation Metrics
P/E TTM	-31.70	-24.92	-8.42	-13.08	-10.43	-10.39	-11.90	-14.47	-13.56	-9.29	-6.87	-9.07
P/B TTM	3.75	5.43	1.90	2.67	2.14	3.42	3.42	4.27	3.68	2.33	2.00	2.14
Market Cap	3.36B	2.46B	872.63M	1.27B	1.05B	985.01M	1.06B	1.23B	1.12B	739.58M	491.96M	560.48M
Enterprise Value	3.22B	2.33B	773.73M	1.17B	925.79M	883.30M	934.96M	1.13B	1.03B	590.36M	391.76M	486.58M
Calculated Values
Free Cash Flow TTM	-71.90M	-65.61M	-70.46M	-47.68M	-46.61M	-74.00M	-73.24M	-68.53M	-72.22M	-63.92M	-61.42M	-57.17M
Net Debt	-135.51M	-132.18M	-98.90M	-101.73M	-119.44M	-101.71M	-124.17M	-100.68M	-96.93M	-149.22M	-100.20M	-73.90M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Insider Transactions

2026-06-22Sale

Owner: Orbimed, Advisors Llc, Or…

Title: -

Shares: 860,123

Price/Share: $45.19

Value: $38,868,958.37

Shares Owned: 219,405

Relationship: TenPercentOwner

Ownership: Indirect

2026-06-17Sale

Owner: Hohl, Benjamin

Title: CHIEF FINANCIAL OFFICER

Shares: 6,018

Price/Share: $43.80

Value: $263,588.40

Shares Owned: 51,000

Relationship: Officer

Ownership: Direct

2026-06-17Sale

Owner: Collins, Helen Louise

Title: CHIEF MEDICAL OFFICER

Shares: 5,000

Price/Share: $43.81

Value: $219,050.00

Shares Owned: 25,000

Relationship: Officer

Ownership: Direct

2026-06-15Sale

Owner: Orbimed, Advisors Llc, Or…

Title: -

Shares: 281,408

Price/Share: $45.02

Value: $12,668,988.16

Shares Owned: 245,728

Relationship: TenPercentOwner

Ownership: Indirect

2026-06-05Sale

Owner: Kunkel, Lori Anne

Title: -

Shares: 10,000

Price/Share: $35.15

Value: $351,500.00

Shares Owned: 51,884

Relationship: Director

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-22	Orbimed, Advisors Llc, Or…	TenPercentOwner	-	Indirect	Sale	860,123	45.19	$38,868,958.37	219,405	4
2026-06-17	Hohl, Benjamin	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	6,018	43.80	$263,588.40	51,000	4
2026-06-17	Collins, Helen Louise	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	5,000	43.81	$219,050.00	25,000	4
2026-06-15	Orbimed, Advisors Llc, Or…	TenPercentOwner	-	Indirect	Sale	281,408	45.02	$12,668,988.16	245,728	4
2026-06-05	Kunkel, Lori Anne	Director	-	Direct	Sale	10,000	35.15	$351,500.00	51,884	4
2026-05-18	Collins, Helen Louise	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	5,000	40.33	$201,650.00	25,000	4
2026-04-17	Collins, Helen Louise	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	5,000	47.09	$235,450.00	25,000	4
2026-03-25	Collins, Helen Louise	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	40,000	35.10	$1,404,000.00	25,000	4
2026-03-17	Collins, Helen Louise	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	5,000	27.76	$138,800.00	25,000	4
2026-03-10	Collins, Helen Louise	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	10,129	30.19	$305,794.51	25,000	4
2026-03-06	Hohl, Benjamin	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	10,000	29.58	$295,800.00	51,000	4
2026-02-17	Collins, Helen Louise	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	45,000	26.17	$1,177,650.00	25,000	4
2026-02-17	Heyman, Richard A.	Director	-	Indirect	Sale	1,230	26.18	$32,201.40	22,647	4
2026-02-06	Lyssikatos, Joseph P	Officer	CHIEF SCIENTIFIC OFFICER	Indirect	Sale	5,000	29.04	$145,200.00	740,188	4
2026-01-20	Heyman, Richard A.	Director	-	Indirect	Sale	1,230	26.71	$32,853.30	23,877	4
2026-01-20	Lyssikatos, Joseph P	Officer	CHIEF SCIENTIFIC OFFICER	Indirect	Sale	20,000	26.64	$532,800.00	745,188	4
2026-01-09	Patel, Anish	Officer	CHIEF OPERATING OFFICER	Indirect	Sale	48,300	28.24	$1,363,992.00	215,011	4
2026-01-09	Heyman, Richard A.	Director	-	Indirect	Sale	4,285	25.00	$107,125.00	25,107	4
2026-01-09	Lyssikatos, Joseph P	Officer	CHIEF SCIENTIFIC OFFICER	Indirect	Sale	91,198	27.02	$2,464,169.96	765,188	4
2025-12-19	Lyssikatos, Joseph P	Officer	CHIEF SCIENTIFIC OFFICER	Indirect	Sale	5,000	16.84	$84,200.00	897,688	4
2025-12-08	Patel, Anish	Officer	CHIEF OPERATING OFFICER	Indirect	Sale	6,663	21.27	$141,722.01	263,311	4
2025-11-19	Lyssikatos, Joseph P	Officer	CHIEF SCIENTIFIC OFFICER	Indirect	Sale	12,500	22.70	$283,750.00	902,688	4
2025-11-17	Kintz, Samuel	Director,Officer	PRESIDENT AND CEO	Indirect	Sale	12,500	21.82	$272,750.00	890,392	4
2025-11-07	Patel, Anish	Officer	CHIEF OPERATING OFFICER	Indirect	Sale	6,667	17.65	$117,672.55	269,974	4
2025-10-20	Lyssikatos, Joseph P	Officer	CHIEF SCIENTIFIC OFFICER	Indirect	Sale	12,500	22.08	$276,000.00	915,188	4
2025-10-17	Kintz, Samuel	Director,Officer	PRESIDENT AND CEO	Indirect	Sale	12,500	21.33	$266,625.00	902,892	4
2025-10-07	Patel, Anish	Officer	CHIEF OPERATING OFFICER	Indirect	Sale	6,667	20.10	$134,006.70	276,641	4
2025-09-29	Hohl, Benjamin	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	3,250	20.40	$66,300.00	23,000	4
2025-09-26	Kintz, Samuel	Director,Officer	PRESIDENT AND CEO	Indirect	Sale	3,700	20.06	$74,222.00	915,392	4
2025-09-26	Lyssikatos, Joseph P	Officer	CHIEF SCIENTIFIC OFFICER	Indirect	Sale	4,000	20.25	$81,000.00	927,688	4
2025-09-23	Lyssikatos, Joseph P	Officer	CHIEF SCIENTIFIC OFFICER	Indirect	Sale	1,500	20.03	$30,045.00	931,688	4
2025-09-23	Kintz, Samuel	Director,Officer	PRESIDENT AND CEO	Indirect	Sale	2,800	20.03	$56,084.00	919,092	4
2025-09-19	Kintz, Samuel	Director,Officer	PRESIDENT AND CEO	Indirect	Sale	1,000	20.25	$20,250.00	921,892	4
2025-09-19	Lyssikatos, Joseph P	Officer	CHIEF SCIENTIFIC OFFICER	Indirect	Sale	7,000	19.56	$136,920.00	933,188	4
2025-09-08	Patel, Anish	Officer	CHIEF OPERATING OFFICER	Indirect	Sale	6,667	20.24	$134,940.08	283,308	4
2025-08-27	Hohl, Benjamin	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	3,250	20.63	$67,047.50	23,000	4
2025-08-21	Lyssikatos, Joseph P	Officer	CHIEF SCIENTIFIC OFFICER	Indirect	Sale	7,500	20.01	$150,075.00	940,188	4
2025-08-20	Kintz, Samuel	Director,Officer	PRESIDENT AND CEO	Indirect	Sale	1,517	20.00	$30,340.00	927,892	4/A
2025-08-19	Kintz, Samuel	Director,Officer	PRESIDENT AND CEO	Indirect	Sale	590	20.00	$11,800.00	929,409	4
2025-08-07	Patel, Anish	Officer	CHIEF OPERATING OFFICER	Indirect	Sale	6,667	18.56	$123,739.52	289,975	4
2025-07-28	Hohl, Benjamin	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	3,250	20.88	$67,860.00	23,000	4
2025-07-21	Lyssikatos, Joseph P	Officer	CHIEF SCIENTIFIC OFFICER	Indirect	Sale	12,500	22.58	$282,250.00	952,688	4
2025-07-17	Kintz, Samuel	Director,Officer	PRESIDENT AND CEO	Indirect	Sale	12,500	22.55	$281,875.00	940,392	4
2025-07-10	Hohl, Benjamin	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	1,000	22.66	$22,660.00	23,000	4
2025-07-07	Patel, Anish	Officer	CHIEF OPERATING OFFICER	Indirect	Sale	6,667	20.22	$134,806.74	296,642	4
2025-06-27	Hohl, Benjamin	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	3,250	21.26	$69,095.00	23,000	4
2025-06-20	Lyssikatos, Joseph P	Officer	CHIEF SCIENTIFIC OFFICER	Indirect	Sale	12,500	21.40	$267,500.00	965,188	4
2025-06-17	Kintz, Samuel	Director,Officer	PRESIDENT AND CEO	Indirect	Sale	12,500	22.42	$280,250.00	952,892	4
2025-06-13	Hohl, Benjamin	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	3,000	22.55	$67,650.00	23,000	4
2025-06-09	Patel, Anish	Officer	CHIEF OPERATING OFFICER	Indirect	Sale	6,667	20.74	$138,273.58	303,309	4
2025-06-03	Kintz, Samuel	Director,Officer	PRESIDENT AND CEO	Indirect	Sale	7,500	20.05	$150,375.00	965,392	4
2025-06-03	Lyssikatos, Joseph P	Officer	CHIEF SCIENTIFIC OFFICER	Indirect	Sale	7,500	20.03	$150,225.00	977,688	4
2025-05-27	Hohl, Benjamin	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	3,250	16.18	$52,585.00	23,000	4
2025-05-19	Kintz, Samuel	Director,Officer	PRESIDENT AND CEO	Indirect	Sale	5,000	16.49	$82,450.00	972,892	4
2025-05-19	Lyssikatos, Joseph P	Officer	CHIEF SCIENTIFIC OFFICER	Indirect	Sale	5,000	16.31	$81,550.00	985,188	4
2025-05-07	Patel, Anish	Officer	CHIEF OPERATING OFFICER	Indirect	Sale	6,667	19.19	$127,939.73	309,976	4
2025-05-02	Kintz, Samuel	Director,Officer	PRESIDENT AND CEO	Indirect	Sale	2,170	20.00	$43,400.00	977,892	4
2025-05-02	Lyssikatos, Joseph P	Officer	CHIEF SCIENTIFIC OFFICER	Indirect	Sale	2,470	20.01	$49,424.70	990,188	4
2025-04-28	Hohl, Benjamin	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	3,250	18.90	$61,425.00	23,000	4
2025-04-21	Lyssikatos, Joseph P	Officer	CHIEF SCIENTIFIC OFFICER	Indirect	Sale	5,000	16.38	$81,900.00	997,688	4
2025-04-17	Kintz, Samuel	Director,Officer	PRESIDENT AND CEO	Indirect	Sale	5,000	16.42	$82,100.00	985,392	4
2025-04-07	Patel, Anish	Officer	CHIEF OPERATING OFFICER	Indirect	Sale	6,667	18.46	$123,072.82	316,643	4
2025-03-27	Hohl, Benjamin	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	3,250	21.33	$69,322.50	23,000	4
2025-03-24	Hohl, Benjamin	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	1,000	22.50	$22,500.00	23,000	4
2025-03-19	Lyssikatos, Joseph P	Officer	CHIEF SCIENTIFIC OFFICER	Indirect	Sale	12,500	20.61	$257,625.00	1,002,688	4
2025-03-17	Kintz, Samuel	Director,Officer	PRESIDENT AND CEO	Indirect	Sale	12,500	20.83	$260,375.00	990,392	4
2025-03-07	Patel, Anish	Officer	CHIEF OPERATING OFFICER	Indirect	Sale	6,667	21.44	$142,940.48	323,310	4
2025-02-27	Hohl, Benjamin	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	3,250	20.41	$66,332.50	13,000	4
2025-02-07	Patel, Anish	Officer	CHIEF OPERATING OFFICER	Indirect	Sale	6,667	21.93	$146,207.31	329,977	4
2025-02-05	Hohl, Benjamin	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	1,000	22.52	$22,520.00	13,000	4
2025-01-27	Hohl, Benjamin	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	3,250	21.59	$70,167.50	13,000	4
2025-01-07	Patel, Anish	Officer	CHIEF OPERATING OFFICER	Direct	Sale	21,700	24.35	$528,395.00	0	4
2025-01-03	Hohl, Benjamin	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	1,000	25.04	$25,040.00	13,000	4
2024-12-30	Hohl, Benjamin	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	900	22.51	$20,259.00	0	4
2024-11-27	Hohl, Benjamin	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	5,250	25.08	$131,670.00	0	4
2024-10-28	Hohl, Benjamin	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	6,250	28.80	$180,000.00	0	4
2024-10-18	Kintz, Samuel	Director,Officer	PRESIDENT AND CEO	Indirect	Sale	924	30.00	$27,720.00	1,002,892	4
2024-10-18	Heyman, Richard A.	Director	-	Direct	Sale	817	30.00	$24,510.00	123,673	4
2024-10-18	Lyssikatos, Joseph P	Officer	CHIEF SCIENTIFIC OFFICER	Indirect	Sale	847	30.00	$25,410.00	1,015,188	4
2024-10-18	Hohl, Benjamin	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	814	30.00	$24,420.00	0	4
2024-10-18	Patel, Anish	Officer	CHIEF OPERATING OFFICER	Indirect	Sale	716	30.00	$21,480.00	343,311	4
2024-10-18	Collins, Helen Louise	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	816	30.00	$24,480.00	0	4
2024-10-15	Heyman, Richard A.	Director	-	Direct	Sale	1,270	27.67	$35,140.90	124,490	4
2024-10-09	Kintz, Samuel	Director,Officer	PRESIDENT AND CEO	Indirect	Sale	16,710	28.30	$472,893.00	1,003,816	4
2024-10-09	Lyssikatos, Joseph P	Officer	CHIEF SCIENTIFIC OFFICER	Indirect	Sale	37,878	28.32	$1,072,704.96	1,016,035	4
2024-10-08	Ballal, Rahul D.	Director	-	Direct	Sale	10,420	28.17	$293,531.40	22,341	4
2024-10-07	Lyssikatos, Joseph P	Officer	CHIEF SCIENTIFIC OFFICER	Indirect	Sale	2,707	27.61	$74,740.27	1,067,180	4
2024-10-07	Kintz, Samuel	Director,Officer	PRESIDENT AND CEO	Indirect	Sale	2,730	27.50	$75,075.00	1,033,793	4
2024-10-07	Hohl, Benjamin	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	1,270	27.51	$34,937.70	0	4
2024-10-04	Heyman, Richard A.	Director	-	Direct	Sale	2,825	27.51	$77,715.75	125,760	4
2024-10-01	Hohl, Benjamin	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	521	27.54	$14,348.34	0	4
2024-10-01	Heyman, Richard A.	Director	-	Direct	Sale	518	27.54	$14,265.72	128,585	4
2024-10-01	Kintz, Samuel	Director,Officer	PRESIDENT AND CEO	Indirect	Sale	526	27.54	$14,486.04	1,048,729	4
2024-10-01	Lyssikatos, Joseph P	Officer	CHIEF SCIENTIFIC OFFICER	Indirect	Sale	527	27.54	$14,513.58	1,077,409	4
2024-09-30	Hohl, Benjamin	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	2,000	25.33	$50,660.00	0	4
2024-09-16	Heyman, Richard A.	Director	-	Direct	Sale	1,270	22.41	$28,460.70	129,103	4
2024-08-29	Lyssikatos, Joseph P	Officer	CHIEF SCIENTIFIC OFFICER	Indirect	Sale	12,000	22.78	$273,360.00	1,077,936	4
2024-08-27	Hohl, Benjamin	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	4,250	22.54	$95,795.00	0	4
2024-08-26	Kintz, Samuel	Director,Officer	PRESIDENT AND CEO	Indirect	Sale	12,000	22.89	$274,680.00	1,049,255	4
2024-08-15	Heyman, Richard A.	Director	-	Direct	Sale	1,270	23.26	$29,540.20	130,373	4
2024-07-31	Heyman, Richard A.	Director	-	Direct	Sale	1,702	27.51	$46,822.02	131,643	4
2024-07-31	Hohl, Benjamin	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	991	27.53	$27,282.23	0	4
2024-07-31	Kintz, Samuel	Director,Officer	PRESIDENT AND CEO	Indirect	Sale	2,270	27.56	$62,561.20	1,061,255	4
2024-07-31	Lyssikatos, Joseph P	Officer	CHIEF SCIENTIFIC OFFICER	Indirect	Sale	3,099	27.56	$85,408.44	1,089,936	4
2024-07-29	Hohl, Benjamin	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	5,250	27.06	$142,065.00	0	4
2024-07-29	Lyssikatos, Joseph P	Officer	CHIEF SCIENTIFIC OFFICER	Indirect	Sale	12,000	27.06	$324,720.00	1,093,035	4
2024-07-25	Kintz, Samuel	Director,Officer	PRESIDENT AND CEO	Indirect	Sale	12,000	25.15	$301,800.00	1,063,525	4
2024-07-16	Patel, Anish	Officer	CHIEF OPERATING OFFICER	Indirect	Sale	1,547	25.01	$38,690.47	344,027	4
2024-07-15	Heyman, Richard A.	Director	-	Direct	Sale	1,270	24.80	$31,496.00	133,345	4
2024-07-12	Hohl, Benjamin	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	3,000	25.07	$75,210.00	0	4
2024-07-01	Lyssikatos, Joseph P	Officer	CHIEF SCIENTIFIC OFFICER	Indirect	Sale	12,000	22.89	$274,680.00	1,105,035	4
2024-06-27	Hohl, Benjamin	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	4,250	22.60	$96,050.00	0	4
2024-06-25	Kintz, Samuel	Director,Officer	PRESIDENT AND CEO	Indirect	Sale	12,000	21.96	$263,520.00	1,075,525	4
2024-06-17	Heyman, Richard A.	Director	-	Direct	Sale	1,270	21.48	$27,279.60	134,615	4
2024-06-06	Patel, Anish	Officer	CHIEF OPERATING OFFICER	Direct	Sale	1,133	20.06	$22,727.98	0	4
2024-05-29	Lyssikatos, Joseph P	Director,Officer	CHIEF SCIENTIFIC OFFICER	Direct	Sale	12,000	22.04	$264,480.00	0	4
2024-05-28	Kintz, Samuel	Director,Officer	PRESIDENT AND CEO	Direct	Sale	12,000	23.59	$283,080.00	0	4
2024-05-28	Hohl, Benjamin	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	4,250	23.55	$100,087.50	0	4
2024-05-16	Orbimed, Capital Gp Vii L…	Director,TenPercentOwner	-	Indirect	Sale	1,033,300	22.14	$22,877,262.00	254,814	4
2024-05-16	Gupta, Rishi	Director,TenPercentOwner	-	Indirect	Sale	1,033,300	22.14	$22,877,262.00	254,814	4
2024-05-16	Heyman, Richard A.	Director	-	Direct	Sale	1,270	23.74	$30,149.80	135,885	4
2024-05-14	Patel, Anish	Officer	CHIEF OPERATING OFFICER	Direct	Sale	1,107	25.00	$27,675.00	0	4
2024-05-09	Patel, Anish	Officer	CHIEF OPERATING OFFICER	Direct	Sale	260	25.06	$6,515.60	0	4
2024-05-06	Patel, Anish	Officer	CHIEF OPERATING OFFICER	Direct	Sale	4,875	22.72	$110,760.00	0	4
2024-05-03	Hohl, Benjamin	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	1,000	22.50	$22,500.00	0	4
2024-04-29	Hohl, Benjamin	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	3,250	16.97	$55,152.50	0	4
2024-04-29	Lyssikatos, Joseph P	Director,Officer	CHIEF SCIENTIFIC OFFICER	Direct	Sale	12,000	18.17	$218,040.00	0	4
2024-04-25	Kintz, Samuel	Director,Officer	PRESIDENT AND CEO	Direct	Sale	12,000	16.89	$202,680.00	0	4
2024-04-15	Heyman, Richard A.	Director	-	Direct	Sale	1,270	20.31	$25,793.70	137,155	4
2024-04-11	Ballal, Rahul D.	Director	-	Direct	Sale	53,400	24.45	$1,305,630.00	22,341	4
2024-04-11	Collins, Helen Louise	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	20,000	25.07	$501,400.00	0	4
2024-04-11	Hohl, Benjamin	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	14,000	24.46	$342,440.00	0	4
2024-04-11	Kintz, Samuel	Director,Officer	PRESIDENT AND CEO	Direct	Sale	47,709	25.04	$1,194,633.36	0	4
2024-04-11	Patel, Anish	Officer	CHIEF OPERATING OFFICER	Direct	Sale	17,500	25.03	$438,025.00	0	4
2024-04-11	Lyssikatos, Joseph P	Director,Officer	CHIEF SCIENTIFIC OFFICER	Direct	Sale	30,000	25.04	$751,200.00	0	4
2024-04-08	Patel, Anish	Officer	CHIEF OPERATING OFFICER	Direct	Sale	4,875	18.95	$92,381.25	2,597	4
2024-04-04	Ballal, Rahul D.	Director	-	Direct	Sale	3,485	19.15	$66,737.75	22,341	4
2024-04-01	Ballal, Rahul D.	Director	-	Direct	Sale	3,237	19.08	$61,761.96	22,341	4
2024-04-01	Lyssikatos, Joseph P	Director,Officer	CHIEF SCIENTIFIC OFFICER	Direct	Sale	12,000	18.63	$223,560.00	0	4
2024-03-27	Hohl, Benjamin	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	3,250	18.47	$60,027.50	0	4
2024-03-25	Kintz, Samuel	Director,Officer	PRESIDENT AND CEO	Direct	Sale	12,000	17.66	$211,920.00	0	4
2024-03-20	Ballal, Rahul D.	Director	-	Direct	Sale	13,278	19.16	$254,406.48	22,341	4
2024-03-19	Heyman, Richard A.	Director	-	Direct	Sale	1,270	14.50	$18,415.00	143,470	4
2024-03-06	Patel, Anish	Officer	CHIEF OPERATING OFFICER	Direct	Sale	4,875	15.64	$76,245.00	7,472	4
2024-02-29	Lyssikatos, Joseph P	Director,Officer	CHIEF SCIENTIFIC OFFICER	Direct	Sale	12,000	16.70	$200,400.00	0	4
2024-02-27	Hohl, Benjamin	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	3,250	16.97	$55,152.50	0	4
2024-02-26	Kintz, Samuel	Director,Officer	PRESIDENT AND CEO	Direct	Sale	12,000	16.96	$203,520.00	0	4
2024-02-15	Heyman, Richard A.	Director	-	Direct	Sale	1,270	17.42	$22,123.40	144,740	4
2024-02-14	5Am, Ventures Vi, L.P., 5…	TenPercentOwner	-	Indirect	Sale	825,000	14.90	$12,292,500.00	635,341	4
2024-02-06	Patel, Anish	Officer	CHIEF OPERATING OFFICER	Direct	Sale	4,875	15.11	$73,661.25	12,347	4
2024-01-31	5Am, Opportunities I (Gp)…	TenPercentOwner	-	Indirect	Sale	500,000	15.00	$7,500,000.00	771,983	4
2024-01-30	Heyman, Richard A.	Director	-	Direct	Sale	1,270	16.41	$20,840.70	146,010	4
2024-01-29	Hohl, Benjamin	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	3,250	15.81	$51,382.50	0	4
2024-01-29	Lyssikatos, Joseph P	Director,Officer	CHIEF SCIENTIFIC OFFICER	Direct	Sale	12,000	15.85	$190,200.00	0	4
2024-01-25	Kintz, Samuel	Director,Officer	President and CEO	Direct	Sale	12,000	15.42	$185,040.00	0	4
2024-01-22	Patel, Anish	Officer	Chief Operating Officer	Direct	Sale	4,875	15.14	$73,807.50	17,222	4
2024-01-02	Patel, Anish	Officer	Chief Operating Officer	Direct	Sale	11,000	15.00	$165,000.00	22,097	4
2023-12-29	Lyssikatos, Joseph P	Director,Officer	Chief Scientific Officer	Direct	Sale	12,000	14.46	$173,520.00	0	4
2023-12-28	Hohl, Benjamin	Officer	Chief Financial Officer	Direct	Sale	2,467	15.07	$37,177.69	0	4
2023-12-26	Patel, Anish	Officer	Chief Operating Officer	Direct	Sale	102	15.01	$1,531.02	35,637	4
2023-12-26	Kintz, Samuel	Director,Officer	President and CEO	Direct	Sale	12,000	14.64	$175,680.00	0	4
2023-12-26	Hohl, Benjamin	Officer	Chief Financial Officer	Direct	Sale	100	15.00	$1,500.00	0	4
2023-12-22	Lyssikatos, Joseph P	Director,Officer	Chief Scientific Officer	Direct	Sale	6,546	13.07	$85,556.22	0	4
2023-12-22	Heyman, Richard A.	Director	-	Direct	Sale	168	13.00	$2,184.00	147,280	4
2023-12-22	Kintz, Samuel	Director,Officer	President and CEO	Direct	Sale	8,175	13.05	$106,683.75	0	4
2023-12-20	Heyman, Richard A.	Director	-	Direct	Sale	2,110	13.02	$27,472.20	147,455	4
2023-12-20	Kintz, Samuel	Director,Officer	President and CEO	Direct	Sale	7,779	13.01	$101,204.79	0	4
2023-12-20	Lyssikatos, Joseph P	Director,Officer	Chief Scientific Officer	Direct	Sale	8,688	13.01	$113,030.88	0	4
2023-11-03	Lyssikatos, Joseph P	Director,Officer	Chief Scientific Officer	Direct	Sale	8,546	13.08	$111,781.68	0	4
2023-11-03	Kintz, Samuel	Director,Officer	President and CEO	Direct	Sale	8,026	13.08	$104,980.08	0	4
2023-09-29	Lyssikatos, Joseph P	Director,Officer	Chief Scientific Officer	Direct	Sale	12,000	13.62	$163,440.00	0	4
2023-09-26	5Am, Opportunities I, L.P…	TenPercentOwner	-	Indirect	Sale	197,500	15.00	$2,962,500.00	854,796	4
2023-09-25	Kintz, Samuel	Director,Officer	President and CEO	Direct	Sale	12,000	13.81	$165,720.00	0	4
2023-08-24	Schwab, Andrew J., 5Am Op…	TenPercentOwner	-	Indirect	Sale	440,000	16.00	$7,040,000.00	887,507	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Institutional Ownership

No data available for chart

2026-03-31

94.59%

Inst. Shares: 59,404,155

Shares Outstanding: 62,799,326

2025-12-31

109.84%

Inst. Shares: 62,237,921

Shares Outstanding: 56,664,226

2025-09-30

93.68%

Inst. Shares: 58,171,177

Shares Outstanding: 62,093,795

2025-06-30

111.94%

Inst. Shares: 58,323,797

Shares Outstanding: 52,105,052

2025-03-31

99.00%

Inst. Shares: 49,549,641

Shares Outstanding: 50,051,283

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	59,404,155	62,799,326	94.59%
2025-12-31	62,237,921	56,664,226	109.84%
2025-09-30	58,171,177	62,093,795	93.68%
2025-06-30	58,323,797	52,105,052	111.94%
2025-03-31	49,549,641	50,051,283	99.00%
2024-12-31	49,107,606	47,072,532	104.32%
2024-09-30	47,260,228	48,267,458	97.91%
2024-06-30	48,245,759	48,075,035	100.36%
2024-03-31	44,400,169	42,045,608	105.60%
2023-12-31	38,928,929	35,546,215	109.52%
2023-09-30	39,039,726	41,030,874	95.15%
2023-06-30	38,321,789	40,961,024	93.56%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Enliven Therapeutics, Inc. (ELVN) — SEC Financial Statements & Analysis

Enliven Therapeutics, Inc. (ELVN) is a pharmaceutical preparations company, incorporated in DE. Enliven Therapeutics, Inc. trades on Nasdaq as: ELVN. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Enliven Therapeutics, Inc. reported a Debt-to-Equity ratio of 0.02x, a Price-to-Book (P/B) ratio of 3.75x (TTM), at a market cap of $3.36B. Figures below are sourced from SEC EDGAR, as-filed.

Debt To Equity: 0.02x
P/B TTM: 3.75x
Market Cap: $3.36B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Enliven Therapeutics, Inc. in?

Enliven Therapeutics, Inc. (ELVN) operates in the Pharmaceutical Preparations industry.

What is ELVN's market cap?

Enliven Therapeutics, Inc. (ELVN) has a market capitalization of $3.36B as of 2026-06-30.

What exchange does ELVN trade on?

Enliven Therapeutics, Inc. (ELVN) trades on the Nasdaq.

Where is Enliven Therapeutics, Inc. incorporated?

Enliven Therapeutics, Inc. is incorporated in DE.